(CHAPEL HILL, N.C.)Drug developer Pozen Inc. said Friday federal regulators have requested an additional study of its experimental heart treatment before considering it for approval.READ MORE

(CHAPEL HILL, N.C.)Drug developer Pozen Inc. said Monday that a cardiovascular disease drug candidate demonstrated bioequivalence to enteric-coated aspirin, possibly paving the way for regulatory app...READ MORE

Among the earnings stories for Thursday, May 8, from AP Financial News: ATLANTA (AP) _ Mirant Corp. said Thursday its first-quarter loss widened on increased fuel costs and lower v...READ MORE

(CHAPEL HILL, N.C.)Drug developer Pozen Inc. on Thursday raised its outlook for 2008 revenue to between $62 million and $68 million, well above Wall Street estimates. Analysts polled by Thomson Finan...READ MORE

(CHAPEL HILL, N.C.)Drug developer Pozen Inc. said Thursday that its first-quarter loss more than tripled on higher operating expenses, though the loss was in-line with Wall Street estimates.READ MORE

(NEW YORK)A Cowen analyst expects limited success for Pozen and GlaxoSmithKline's migraine drug Treximet due to generic competition and reimbursement questions.READ MORE

(NEW YORK) Continental Airlines Inc. said Thursday that soaring fuel costs pushed it to a loss for the first quarter, and it plans to retrench by mothballing planes and reducing flights. Ho...READ MORE